

Summary Public Assessment Report

Empagliflozin Labiana (empagliflozin)

SE/H/2694/001-002/DC

Summary Public Assessment Report

Empagliflozin Labiana
empagliflozin

Film-coated tablet, 10 mg, 25 mg

This is a summary of the public assessment report (PAR) for Empagliflozin Labiana. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Empagliflozin Labiana and what is it used for?

The product is a 'generic medicine'. This means that it is similar to a 'reference medicine' already authorised in the European Union (EU) called Jardiance.

The product is used in the treatment of Type 2 diabetes mellitus.

- Empagliflozin Labiana is used to treat type 2 diabetes in adults and children aged 10 years and older that cannot be controlled by diet and exercise alone.
- Empagliflozin Labiana can be used without other medicines in patients who cannot take metformin (another diabetes medicine).
- Empagliflozin Labiana can also be used with other medicines for the treatment of diabetes. These may be medicines taken by mouth or given by injection such as insulin.

How does Empagliflozin Labiana work?

Empagliflozin Labiana contains the active substance empagliflozin.

Empagliflozin Labiana is a member of a group of medicines called sodium glucose co-transporter-2 (SGLT2) inhibitors.

How is Empagliflozin Labiana used?

The pharmaceutical form is Film-coated tablet for oral use.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Empagliflozin Labiana have been shown in studies?

No additional studies were needed as the product is a generic medicine considered to be bioequivalent to the reference medicine, Jardiance. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the possible side effects from Empagliflozin Labiana?

Because the product is a generic medicine, its benefits and possible side effects are taken as being the same as the reference medicine.

Why is Empagliflozin Labiana approved?

It was concluded that, in accordance with EU requirements, the product has been shown to have comparable quality and is bioequivalent to the reference medicine. Therefore, the Swedish Medical Products Agency decided that, as for Jardiance, the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Empagliflozin Labiana?

A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well. For more details, please see the full PAR for Empagliflozin Labiana on the following website: [MRI - Home](#).

Other information about Empagliflozin Labiana

The full PAR for Empagliflozin Labiana can be found on the following website: [MRI - Home](#). For more information about treatment with Empagliflozin Labiana, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2026-06.